Statins cannot touch it. Neither can diet or exercise. Lipoprotein(a), a cholesterol-like particle hardwired into a person’s DNA, circulates at elevated levels in roughly one in five adults and raises the risk of heart attacks, strokes, and aortic valve disease. For decades, doctors have been able to measure it but not treat it. That is now changing. Novartis, Amgen, and Eli Lilly are each advancing drugs designed to slash Lp(a) levels, setting up what could become the most consequential cardiovascular drug race since the arrival of PCSK9 inhibitors a decade ago.
The stakes are enormous. If any of these candidates proves in a large outcomes trial that lowering Lp(a) prevents cardiac events, it would open a treatment market covering tens of millions of patients worldwide who currently have no pharmacological option. If the trials fail, the entire Lp(a) hypothesis, supported by genetics but unproven in randomized medicine, goes back to the drawing board.
Why Lp(a) matters
Unlike LDL cholesterol, which responds to statins, Lp(a) levels are almost entirely inherited and remain stable throughout a person’s life. A 2022 European Atherosclerosis Society consensus statement classified Lp(a) as a causal, independent risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis. The document recommended that every adult have Lp(a) measured at least once and flagged levels above 50 mg/dL (approximately 125 nmol/L) as clinically significant.
That threshold captures about 20% of the global population. For those individuals, the genetic evidence is stark: Mendelian randomization studies have shown that lifelong exposure to high Lp(a) tracks with higher rates of coronary artery disease, independent of LDL levels. The missing piece has always been proof that a drug, not just a favorable gene variant, can reverse that risk.
Novartis: pelacarsen and the Lp(a)HORIZON setback
Novartis was the first major drugmaker to push an Lp(a)-lowering therapy into a large cardiovascular outcomes trial. Pelacarsen, an antisense oligonucleotide injected under the skin once a month, was tested in the Lp(a)HORIZON trial, which enrolled more than 8,000 patients with established cardiovascular disease and Lp(a) levels above 70 mg/dL.
Results presented at the American Heart Association Scientific Sessions in November 2024 showed that pelacarsen reduced Lp(a) by roughly 80% but did not meet the trial’s primary endpoint of reducing major adverse cardiovascular events compared with placebo. The finding was a significant disappointment for the field and raised hard questions: Was the Lp(a) reduction not large enough in absolute terms? Was the trial too short? Or does Lp(a) lowering simply not translate into clinical benefit the way LDL lowering does?
Novartis and outside researchers have pointed to several possible explanations, including the trial’s event rate and the specific patient population enrolled. But as of spring 2026, the Lp(a)HORIZON miss remains the most important data point in the field, and every subsequent trial will be interpreted partly in its shadow.
Amgen: olpasiran and the OCEAN(a) trial
Amgen’s candidate, olpasiran, uses a different technology: small interfering RNA (siRNA) that silences the gene responsible for Lp(a) production in the liver. In earlier-phase studies, olpasiran demonstrated Lp(a) reductions exceeding 95% at higher doses, a deeper cut than pelacarsen achieved.
The company’s Phase 3 OCEAN(a) outcomes trial is enrolling patients with atherosclerotic cardiovascular disease and Lp(a) above 200 nmol/L. Its primary endpoint is a composite of major adverse cardiovascular events, including cardiovascular death, heart attack, stroke, and urgent coronary revascularization. According to the trial registry, the estimated primary completion date is October 2026, making a readout possible in late 2026 or early 2027.
OCEAN(a) carries added weight after the Lp(a)HORIZON results. If olpasiran’s deeper Lp(a) reduction produces a statistically significant reduction in events, it would validate the Lp(a) hypothesis and suggest that the degree of lowering matters. If it also misses, the therapeutic class faces a much steeper path to approval.
Eli Lilly: muvalaplin and the oral advantage
Eli Lilly’s approach stands apart on a practical level. Muvalaplin is a once-daily oral pill, not an injection. It works by blocking the physical assembly of the Lp(a) particle, disrupting the interaction between apolipoprotein(a) and apolipoprotein B before the particle forms.
A Phase 1 trial published in JAMA Network Open in 2023 established muvalaplin’s safety profile and confirmed dose-dependent Lp(a) reductions of up to 65% over a two-week dosing period. Lilly has since advanced the drug into Phase 2 testing, including the KRAKEN trial, which is evaluating longer-term efficacy and safety in a larger patient population.
Muvalaplin trails its competitors in development timelines. It has not yet entered a Phase 3 outcomes trial, and years of additional testing lie ahead before any regulatory filing. But the oral format gives it a potential commercial edge that injectable rivals cannot easily match. For a condition that requires lifelong treatment, a daily pill could dramatically improve patient adherence compared with monthly or quarterly injections, particularly in primary care settings where most cardiovascular risk management happens.
What the Lp(a)HORIZON miss means for the field
The pelacarsen results did not kill the Lp(a) hypothesis, but they complicated it. Several factors could explain why an 80% Lp(a) reduction did not translate into fewer events in that trial. Lp(a) is measured in mass units (mg/dL) or molar units (nmol/L), and the relationship between percentage reduction and absolute particle removal is not straightforward. Patients with very high baseline Lp(a) may retain clinically meaningful levels even after an 80% drop. The trial’s median follow-up period and event accrual patterns also matter.
Researchers have noted that LDL-lowering trials took decades and multiple attempts before the statin class proved its worth in outcomes studies. The Lp(a) field may follow a similar arc, where early trials refine the target population, dosing, and endpoint definitions before a definitive positive result emerges. OCEAN(a), with its deeper Lp(a) suppression and slightly different patient selection, represents the next critical test.
Where the race stands in spring 2026
No approved drug for lowering Lp(a) exists. The competitive landscape breaks down along three axes: mechanism, delivery, and development stage.
Novartis has the most complete dataset but also the most sobering result. Pelacarsen’s future likely depends on subgroup analyses from Lp(a)HORIZON and whether Novartis pursues additional trials or repositions the drug for specific patient populations, such as those with aortic stenosis.
Amgen is closest to delivering the next major verdict. OCEAN(a) is the trial the cardiology community is watching most closely, and its readout will shape regulatory and commercial strategy across the entire Lp(a) space.
Lilly is the furthest from market but holds a differentiation advantage. If the Lp(a) hypothesis is validated by OCEAN(a) or a future trial, an oral option could capture significant market share simply by being easier to take.
For the roughly 1.5 billion people worldwide estimated to carry Lp(a) above 50 mg/dL, the next 18 months will determine whether a treatable risk factor finally gets a treatment, or whether the genetics-to-therapy pipeline hits another wall.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
